Status:
COMPLETED
Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Shoulder Hand Syndrome
Complex Regional Pain Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Shoulder-hand syndrome (SHS) in stroke patients is painful and lowers quality of life. Unfortunately, the cause of SHS is not known, diagnosing SHS can be difficult, and treating it can be hard. Recen...
Eligibility Criteria
Inclusion
- Subjects are required to be 18 years of age or older and have a presumptive diagnosis of SHS post-stroke with a minimum visual analog scale of 40mm (greater than 40mm is considered moderate pain).
Exclusion
- Subjects will be excluded from the study if they have significant cognitive impairment (mini-mental state examination \<23) and language deficits (difficulty cooperating due to aphasia) as this may affect their response to the outcome measures. Subjects with uncontrolled hypertension (\>180/110), septicemia, and brachial plexus injuries will be excluded. Patients who are blind and deaf will also be excluded, as they will be unable to adequately complete the post-procedure survey and VAS. Patients on anticoagulation medications will also be excluded on a case-by-case basis and medications will be held prior to injection if required for safety. Patients with INR \>1.5 will be excluded.
Key Trial Info
Start Date :
October 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 14 2018
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03291197
Start Date
October 15 2017
End Date
October 14 2018
Last Update
September 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Elisabeth Bruyere Hospital
Ottawa, Ontario, Canada, K1N5C8